Finance

Lists
KPTI:NASDAQ
Karyopharm Therapeutics Inc
1,68 US$
-2,33%
(-0,040) 1D
9 სექ, 14:10:32 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KPTI...
Open
1,72 US$
High
1,75 US$
Low
1,65 US$
Mkt. cap
38,10 მლნ.
Avg. vol.
2,23 მლნ.
Volume
460,18 ათ.
52-wk high
10,99 US$
52-wk low
1,65 US$
EPS
-12,84 US$
Beta
0,95
Shares outstanding
22,68 მლნ.
No. of employees
228
Open
1,72 US$
High
1,75 US$
Low
1,65 US$
Mkt. cap
38,10 მლნ.
Avg. vol.
2,23 მლნ.
Volume
460,18 ათ.
52-wk high
10,99 US$
52-wk low
1,65 US$
EPS
-12,84 US$
Beta
0,95
Shares outstanding
22,68 მლნ.
No. of employees
228
About Karyopharm Therapeutics Inc
CEO-
Employees228
Founded2008
Headquartersნიუტონი, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to KPTI in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KPTI in the last 3 months.
Highest
Current 1,68 US$
11,00 US$ (+554,76%)
Average
6,54 US$ (+289,29%)
Lowest
3,00 US$ (+78,57%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
3,68 US$
+119%
09/01/2026
Brian Abrahams
RBC Capital
Buy
Maintained
8,00 US$
+376,2%
08/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
11,00 US$
+554,8%
07/31/2026
Colleen M. Kusy
Robert W. Baird
Hold
Downgraded
-
-
07/31/2026
Edward Tenthoff
Piper Sandler
Buy
Maintained
7,00 US$
+316,7%
07/31/2026
Robert Burns
H.C. Wainwright
Hold
Downgraded
3,00 US$
+78,6%
07/31/2026
Unknown Analyst
Leerink Partners
Hold
Reiterated
7,00 US$
+316,7%
05/15/2026
Michael King
Rodman & Renshaw
Buy
Initiated
28,00 US$
+1 566,7%
03/09/2026
Last report
13 აგვ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-2,32 US$ / -1,39 US$
-66,91%miss
Revenue / Est. (USD)
33,43 მლნ. / 32,19 მლნ.
+3,85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
44,04 მლნ.
34,08 მლნ.
35,07 მლნ.
33,43 მლნ.
Cost of goods sold
32,66 მლნ.
29,15 მლნ.
35,14 მლნ.
30,04 მლნ.
Cost of revenue
32,66 მლნ.
29,15 მლნ.
35,14 მლნ.
30,04 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,61 მლნ.
22,77 მლნ.
26,68 მლნ.
25,92 მლნ.
Operating expense
26,61 მლნ.
22,77 მლნ.
26,68 მლნ.
25,92 მლნ.
Total operating expenses
59,26 მლნ.
51,92 მლნ.
61,83 მლნ.
55,96 მლნ.
Operating income
-15,22 მლნ.
-17,84 მლნ.
-26,76 მლნ.
-22,53 მლნ.
Other non operating income
-7,42 მლნ.
-10,04 მლნ.
16,41 მლნ.
-32,08 მლნ.
EBT including unusual items
-33,09 მლნ.
-102,26 მლნ.
-22,39 მლნ.
-67,02 მლნ.
EBT excluding unusual items
-33,09 მლნ.
-39,90 მლნ.
-22,39 მლნ.
-67,02 მლნ.
Income tax expense
34,00 ათ.
-67,00 ათ.
1,00 ათ.
-
Effective tax rate
-0,10%
0,07%
-
-
Other operating expenses
-
-
-
-
Net income
-33,13 მლნ.
-102,20 მლნ.
-22,39 მლნ.
-67,02 მლნ.
Net profit margin
-75,21%
-299,89%
-63,86%
-200,48%
Earnings per share
-3,82
-2,23
-1,24
-2,32
Interest and investment income
553,00 ათ.
607,00 ათ.
511,00 ათ.
722,00 ათ.
Interest expense
-11,01 მლნ.
-12,62 მლნ.
-12,55 მლნ.
-13,14 მლნ.
Net interest expenses
-10,46 მლნ.
-12,01 მლნ.
-12,04 მლნ.
-12,42 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-15,10 მლნ.
-17,82 მლნ.
-26,75 მლნ.
-22,52 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები